Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Seagen Inc (NQ: SGEN )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 228.91 (1)
Ask (Size) 228.96 (22)
Prev. Close 228.74
Today's Range N/A - N/A
52wk Range 211.77 - 228.94
Shares Outstanding 181,934,500
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Steal-of-a-Deal Stocks to Snap Up Right Now
Here are three steal-of-a-deal stocks that offer meaningful upside for investors looking for stocks that are on sale now. 
Via InvestorPlace
Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
Pfizer Inc (NYSE: PFE) is among the many pharmaceutical companies that turned to oncology in response to sinking demand for its COVID-19 products and near patent expiration dates for its several... 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property

Performance

More News

Read More
Get Rich Quick with These 7 Growth Stocks to Buy Now
Via InvestorPlace
7 Dividend Stocks to Buy at a 52-Week Low
Via InvestorPlace
Pfizer’s 2024 Comeback: A Dividend Gem in the Pharma Market
Via InvestorPlace
Looking Into Seagen's Recent Short Interest
Via Benzinga
Seagen Inc. (NASDAQ: SGEN) is a Leading Gainer in 12/12 Morning Trading
Via Investor Brand Network
What the Options Market Tells Us About Seagen
Via Benzinga
3 Pharma Stocks Could Be the Pills Your Portfolio Needs
Via InvestorPlace
How To Earn $500 A Month From Pfizer Stock
Via Benzinga
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
Via Benzinga
3 Stocks That Are About to Get Absolutely Crushed
Via InvestorPlace
$100 Invested In Seagen 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Pfizer's 2030 Vision Bolstered By Seagen Deal, Analyst Cuts Price Target Amid Conservative 2024 Forecast
Via Benzinga
Pfizer's 2024 Outlook Disappointed Wall Street, But Where Will the Stock Be in 5 Years?
Via The Motley Fool
3 Sleepy Stocks Ready to Wake up in 2024
Via InvestorPlace
Pfizer's Dividend Yield Is 5.7%, Plus Humana And Shake Shack On CNBC's 'Final Trades'
Via Benzinga
Pfizer Stock Tumble Steepens As Seagen Guidance Update Disappoints
Via Investor's Business Daily
Why Is US Pharma Giant Pfizer Stock Trading Lower Today?
Via Benzinga
Pfizer Clears Required Regulatory Hurdles To Complete $43B Seagen Acquisition
Via Benzinga
Bristol Myers Squibb Further Diversifies Oncology Portfolio With Mega $8.4B Deal
Via Benzinga
ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma
From Seagen Inc.
Via Business Wire
3 Blue-Chip Stocks Set to Make a Comeback in 2024
Via InvestorPlace
TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
From Seagen Inc.
Via Business Wire
ImmunoGen Stock Nearly Doubled On Thursday: What Happened?
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.